Cardiovascular Results For Dapagliflozin Point To Sglt2 Use To Prevent Heart Failure | Latest News RSS feed

Cardiovascular Results For Dapagliflozin Point To Sglt2 Use To Prevent Heart Failure - Latest News


Diabetes drug might also ease heart failure risks

Type 2 diabetics who took Farxiga (dapagliflozin) saw their odds of hospitalization for heart failure ... Wiviott, a cardiovascular medicine specialist at Brigham and Women's Hospital in Boston. "When ... read more

Cardiovascular Radiance For Jardiance

It seems likeliest that the result points to an effect common to all the SGLT2 inhibitors, but until the cardiovascular outcomes studies ... such as hospitalisation for heart failure and diabetes keto... read more

AstraZeneca to present scientific advances in Cardiovascular and Metabolic Diseases at 2017 ADA Scientific Sessions

AstraZeneca will also present analyses from DURATION-8, evaluating the investigational use of exenatide extended-release in combination with dapagliflozin ... Heart Failure and Death in New Users of S... read more

Looking for another news?


New Analysis Finds Hope for Reducing Heart Failure

Since then, both canagliflozin and dapagliflozin have shown similar results for heart failure, but only the CVOT for dapagliflozin, the DECLARE trial, had heart failure as a primary end point ... card... read more


SGLT2 inhibitors: an emerging option for cardiologists?

With studies showing potential for SGLT2 inhibitors in heart failure ... of the cardiovascular benefits of SGLT2 inhibitors, launching a study of type 2 diabetes patients on various SGLT2 inhibitors i... read more

Top heart disease and stroke research advances of 2017

Economic recession affects the cardiovascular ... heart failure for people with diabetes A large international study in Circulation showed lower rates of death and heart failure for diabetes patients ... read more

Study: Type 2 diabetes pill Jardiance cuts risk of death

The study found Jardiance reduced deaths from heart complications by 38 percent, deaths from any cause by 32 percent and hospitalizations due to chronic heart failure ... sugar to trying to prevent ca... read more

AstraZeneca to Present New Data Demonstrating Breadth of Research Portfolio in Renal Disease at ASN Kidney Week 2018

35 scientific data presentations and publications, including new evidence for LOKELMA ™ (sodium zirconium cyclosilicate) in hyperkalemia and FARXIGA ® (dapagliflozin ... and those on common medication... read more

Amarin Corporation PLC (AMRN) CEO John Thero Presents Primary REDUCE-IT Trial Results Following Presentation at 2018 Scientific Sessions of American Heart Association ...

Amarin Corporation PLC (NASDAQ:AMRN) Primary REDUCE-IT Trial Results Following Presentation ... may have a trends for lower heart disease but they don't cardiovascular a total mortality. Some did. On ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us